Key facts
- This page summarizes Miranda Jayne Toledano's Form 4 filing for Compass Therapeutics, Inc. (CMPX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 29 Jun 2021, 14:31.
Miranda Jayne Toledano - 25 Jun 2021 Form 4 Insider Report for Compass Therapeutics, Inc. (CMPX)
- Reporting relationship
- Director
- Issuer ticker
- CMPX
- Reported as of
- 25 Jun 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 29 Jun 2021, 14:31:38 UTC
- Next SEC filing
- 15 Sep 2021
- Source filing
- View source filing
- Reporting owner signature
- Patrick J. Kinney, Jr., as attorney-in-fact for Miranda Toledano
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Miranda Jayne Toledano filed Form 4 for Compass Therapeutics, Inc. (CMPX) on 29 Jun 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CMPX
transaction
Common Stock, $.0001 Par Value
Other
- Transaction value
- Shares
- +1,791,549
- Change %
- Price
- Shares after
- 1,791,549
- Date
- 25 Jun 2021
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CMPX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +50,000
- Change %
- Price
- $0.000000
- Shares after
- 50,000
- Date
- 25 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock, $.0001 Par Value
- Underlying amount
- 50,000
- Exercise price
- $4.90
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The reporting person acquired 1,791,549 shares of the issuer's common stock as consideration in connection with the acquisition of TRIGR Therapeutics, Inc. by the issuer. The merger agreement, which was entered into on May 13, 2021, placed a negotiated value on the issuer's common stock of $5.85 a share. Of the 1,791,549 shares issued to the reporting person in the merger, 283,648 shares are currently being held in escrow and are subject to forfeiture for the purposes described in the merger agreement.
Footnote F2
The option has a term of 10 years and vest in equal monthly installments over the 48 month period commencing on July 25, 2021.